Healthcare Equipment and Supplies
Company Overview of CardioDx, Inc.
CardioDx, Inc., a molecular diagnostics company, develops tests for coronary artery disease (CAD), cardiac arrhythmia, and heart failure. It develops Corus CAD, a blood test that helps primary care clinicians and cardiologists to assess whether or not non-diabetic patient’s chest discomfort or other symptoms are due to obstructive CAD. The company serves customers in the United States. CardioDx, Inc. was incorporated in 2003 and is based in Redwood City, California.
600 Saginaw Drive
Redwood City, CA 94063
Founded in 2003
Key Executives for CardioDx, Inc.
Founder, Chief Executive Officer, President and Director
Senior Vice President of Human Resources
Vice President of Development
Senior Vice President of Sales
Compensation as of Fiscal Year 2015.
CardioDx, Inc. Key Developments
CardioDx, Inc. Announces Positive Results from Clinical Utility Study
Apr 1 15
CardioDx, Inc. announced the publication of a new study examining the effect of the use of an age, sex, and gene expression score on clinical decision-making and the rate of further cardiac evaluation in symptomatic female patients in the outpatient setting. The study examined the use of the Corus CAD test, a blood test which incorporates age, sex, and gene expression, in 320 women presenting with stable symptoms suggestive of obstructive coronary artery disease (CAD). The study indicated that women with low Corus CAD test scores (=15) were significantly less likely to be referred for further cardiac evaluation (OR 0.013, p<0.0001) by their primary care clinicians within 45 days of follow-up. Only 4% of women (10/248) with low Corus CAD test scores received further testing for obstructive CAD. The Corus CAD test is the first and only commercially available blood-based test incorporating age, sex, and gene expression measurements that provides a current-state assessment of obstructive CAD in non- diabetic patients presenting with non-acute typical or atypical symptoms. The study included 320 women presenting to 16 primary care providers across 9 practice sites and 6 states. The mean Corus CAD test score was 10.3±8.2, with a range of 1 (corresponding to a 1% likelihood of obstructive CAD) to 38 (corresponding to a 62% likelihood of obstructive CAD). Overall, 77.5% of women (248/320) had low Corus CAD test scores. The referral rate for further cardiac evaluation was 4% (10/248) among women with low Corus CAD test scores versus 83.3% (60/72) among women with elevated scores (p<0.0001).
CardioDx, Inc. Announces the Results of Study Demonstrating the Benefits of the Corus Cad Gene Expression Test
Oct 20 14
CardioDx, Inc. announced the presentation of the study. The study evaluated the clinical utility of the Corus CAD blood-based gene expression test in the assessment of 518 African American patients presenting with symptoms suggestive of obstructive coronary artery disease (CAD) in a primary care setting. The results demonstrate the impact of Corus CAD score on clinician decision-making: Patients with low-Corus CAD scores (= 15) had a 95% decreased rate of referral for advanced cardiac testing compared to patients with elevated (> 15) Corus CAD scores (8/214 vs. 227/304). By ruling out obstructive CAD early in the work-up, the Corus CAD test was able to help clinicians avoid unnecessary referrals to cardiology or advanced cardiac testing when their patients' symptoms are due to non-cardiac causes. Corus CAD is the first and only commercially available blood-based test incorporating age, sex, and gene expression measurements that provides a current-state assessment of obstructive CAD in non-diabetic patients presenting with non-acute typical or atypical symptoms. The results of the gene expression measurements are combined with the patient's age and sex in an algorithm that delivers a score representing the likelihood of obstructive CAD. With a 96% negative predictive value, Corus CAD can help clinicians accurately rule out obstructive CAD as the source of their patients' symptoms, so that they may investigate other non-cardiac causes. Of the 518 patients enrolled in the study, 41% (n=214) had a low Corus CAD score, demonstrating that the test has high relevance to clinical practice for ruling out obstructive CAD in a significant number of patients in everyday practice. The authors concluded that Corus CAD improved care for those patients with a low score by avoiding unnecessary, and potentially invasive, advanced diagnostic testing.
CardioDx Announces New Leadership Appointments
Apr 28 14
CardioDx, Inc. announced that diagnostics industry veterans Melinda Griffith, J.D., and Doug Ross, M.D., Ph.D., have joined the executive team as Head of Corporate Development and General Counsel, and Chief Scientific Officer, respectively. In addition, the company has announced the appointment of James Tobin and Andrew Guggenhime to the Board of Directors. Andrew Guggenhime will be transitioning from his role as Chief Financial Officer of CardioDx to this new position. Prior to joining CardioDx, Ms. Griffith served in multiple executive management positions at Clarient, Inc. Most recently, Dr. Ross was an independent consultant serving as Acting Chief Scientific Officer of the Medical Science division of Life Technologies Corporation, helping guide research and development as well as strategic partnerships initiatives. With more than 40 years of healthcare industry experience, Mr. Tobin previously served as CEO and President of Boston Scientific Corporation. Mr. Guggenhime brings strong leadership, management, business, and financial expertise from the life sciences sector to the CardioDx Board of Directors. Mr. Guggenhime joined CardioDx as Chief Financial Officer in September 2011.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 25, 2015
December 18, 2014